| |
With a 60+ year legacy of excellence in bioscience manufacturing, Puerto Rico is a hub for groundbreaking discoveries in the region & beyond. Local talent, tax benefits & the island's decades of expertise fuel companies like CytoImmune & OcyonBio. Learn more.
|
|
Today’s Big NewsFeb 1, 2024 |
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle.
|
|
| By Kevin Dunleavy With Merck reporting a whopping $25 billion sales haul for Keytruda on Thursday, the PD-1 cancer superstar appears to be the world’s top-selling drug in 2023. Keytruda looks set to take over the top spot from Pfizer and BioNTech’s Comirnaty, which ruled the previous two years, scoring sales of $55.9 billion in 2022 and $55.1 billion in 2021. |
|
|
|
By Fraiser Kansteiner As Vyvanse generics take a chunk out of Takeda's sales, the company is hopeful its roster of new drugs, including its dengue fever vaccine Qdenga, can keep revenues intact. |
By Annalee Armstrong Think Roche is out of the Alzheimer’s disease business? Think again. |
By Andrea Park Revvity’s first several months as a standalone company haven’t all been smooth sailing. |
|
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way,providing a robust and adaptable manufacturing platform for gene therapy breakthroughs.
|
|
By Kevin Dunleavy Even after the acquisitions of Prometheus, for $10.8 billion in 2023, and Acceleron, for $11.5 billion in 2021, Merck is ready to make more deals in the $1 billion to $15 billion range, according to CEO Rob Davis. |
By Nick Paul Taylor Roche has removed eight phase 1 and 2 oncology and neurology candidates from its pipeline as part of a set of “trade-offs” intended to “increase the overall portfolio value and speed up development.” |
By Conor Hale Delfi's DNA fragmentome-based liquid biopsy test is currently limited to research use only. Immunocore will help explore its potential in predicting patient benefit for its bispecific T-cell receptor immunotherapies. |
By Angus Liu As Roche CEO Thomas Schinecker sees it, the Swiss pharma made a “major achievement” in 2023. Despite a sharp decline in COVID-related sales, the company was able to grow overall revenues thanks in large part to the performance of eye disease drug Vabysmo. |
By Max Bayer Merck plans to launch more phase 3 trials in 2024 than it did in 2023, underscoring the company's mid-to-late-stage growth plan. Meanwhile, CEO Rob Davis says the company is hunting for more mid-sized deals. |
By Andrea Park As clinical trials of its brain-computer interface progress, Synchron is laying the groundwork for the technology’s eventual commercial rollout. |
By Eric Sagonowsky Despite litigation and denouncements from the biopharma industry, Medicare price negotiations under the Inflation Reduction Act are rolling on. And today, the government is sending out its first round of offers on affected drugs. |
By Gabrielle Masson Former Eisai leader Ivan Cheung, the face of approved Alzheimer's disease medicine Leqembi, is taking the top spot at NextPoint Therapeutics. |
Fierce podcastsDon’t miss an episode |
| | While it’s a known fact that women, on average, live longer than men, a recent report unveils a nuanced reality—women also spend more of their lives grappling with poor health. This week on “The Top Line,” Ayla Ellison, editor-in-chief of Fierce Healthcare and Life Sciences, explores the root causes behind this disparity and the multifacted nature of the women’s health gap. |
|
|---|
|
|
|
This white paper explains how Resilience utilizes a Stage-Gate approach to technology transfer and biomanufacturing. Built on proven methods used across industries, the Stage-Gate approach mitigates risk while shortening cycle times throughout the project lifecycle. Download now.
|
|
| Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
